A citation-based method for searching scientific literature

Elizabeth J Phillips, Chonlaphat Sukasem, Michelle Whirl-Carrillo, Daniel J Müller, Henry M Dunnenberger, Wasun Chantratita, Barry Goldspiel, Yuan-Tsong Chen, Bruce C Carleton, Alfred L George, Taisei Mushiroda, Teri Klein, Roseann S Gammal, Munir Pirmohamed. Clin Pharmacol Ther 2018
Times Cited: 97







List of co-cited articles
774 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
K E Caudle, A E Rettie, M Whirl-Carrillo, L H Smith, S Mintzer, M T M Lee, T E Klein, J T Callaghan. Clin Pharmacol Ther 2014
140
26

Medical genetics: a marker for Stevens-Johnson syndrome.
Wen-Hung Chung, Shuen-Iu Hung, Hong-Shang Hong, Mo-Song Hsih, Li-Cheng Yang, Hsin-Chun Ho, Jer-Yuarn Wu, Yuan-Tsong Chen. Nature 2004
26

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena,[...]. Clin Pharmacol Ther 2015
412
26

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
216
25

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.
Mark McCormack, Ana Alfirevic, Stephane Bourgeois, John J Farrell, Dalia Kasperavičiūtė, Mary Carrington, Graeme J Sills, Tony Marson, Xiaoming Jia, Paul I W de Bakker,[...]. N Engl J Med 2011
573
20

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Mary V Relling, Matthias Schwab, Michelle Whirl-Carrillo, Guilherme Suarez-Kurtz, Ching-Hon Pui, Charles M Stein, Ann M Moyer, William E Evans, Teri E Klein, Federico Guillermo Antillon-Klussmann,[...]. Clin Pharmacol Ther 2019
161
18


Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
Pei Chen, Juei-Jueng Lin, Chin-Song Lu, Cheung-Ter Ong, Peiyuan F Hsieh, Chih-Chao Yang, Chih-Ta Tai, Shey-Lin Wu, Cheng-Hsien Lu, Yung-Chu Hsu,[...]. N Engl J Med 2011
409
16

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
259
15

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
546
15

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Ursula Amstutz, Neil H Shear, Michael J Rieder, Soomi Hwang, Vincent Fung, Hidefumi Nakamura, Mary B Connolly, Shinya Ito, Bruce C Carleton. Epilepsia 2014
114
14

Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.
Chun-Bing Chen, Yi-Hsin Hsiao, Tony Wu, Mo-Song Hsih, Wichittra Tassaneeyakul, Teekayu P Jorns, Chonlaphat Sukasem, Chien-Ning Hsu, Shih-Chi Su, Wan-Chun Chang,[...]. Neurology 2017
68
20

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.
Takeshi Ozeki, Taisei Mushiroda, Amara Yowang, Atsushi Takahashi, Michiaki Kubo, Yuji Shirakata, Zenro Ikezawa, Masafumi Iijima, Tetsuo Shiohara, Koji Hashimoto,[...]. Hum Mol Genet 2011
335
14

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
M S Hershfield, J T Callaghan, W Tassaneeyakul, T Mushiroda, C F Thorn, T E Klein, M T M Lee. Clin Pharmacol Ther 2013
132
14

Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
580
14

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
245
14

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Jacob T Brown, Jeffrey R Bishop, Katrin Sangkuhl, Erika L Nurmi, Daniel J Mueller, Jean C Dinh, Andrea Gaedigk, Teri E Klein, Kelly E Caudle, James T McCracken,[...]. Clin Pharmacol Ther 2019
53
24

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Shuen-Iu Hung, Wen-Hung Chung, Shiou-Hwa Jee, Wen-Chieh Chen, Yun-Ting Chang, Woan-Ruoh Lee, Shu-Ling Hu, Meng-Tse Wu, Gwo-Shing Chen, Tak-Wah Wong,[...]. Pharmacogenet Genomics 2006
436
12

Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Wen-Hung Chung, Wan-Chun Chang, Yun-Shien Lee, Ying-Ying Wu, Chih-Hsun Yang, Hsin-Chun Ho, Ming-Jing Chen, Jing-Yi Lin, Rosaline Chung-Yee Hui, Ji-Chen Ho,[...]. JAMA 2014
166
12


Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.
Y Saito, L K Stamp, K E Caudle, M S Hershfield, E M McDonagh, J T Callaghan, W Tassaneeyakul, T Mushiroda, N Kamatani, B R Goldspiel,[...]. Clin Pharmacol Ther 2016
71
16

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
M A Martin, T E Klein, B J Dong, M Pirmohamed, D W Haas, D L Kroetz. Clin Pharmacol Ther 2012
116
11

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.
Wichittra Tassaneeyakul, Somsak Tiamkao, Thawinee Jantararoungtong, Pei Chen, Shu-Yi Lin, Wei-Hsuan Chen, Parinya Konyoung, Usanee Khunarkornsiri, Narong Auvichayapat, Kasemsin Pavakul,[...]. Epilepsia 2010
176
11

HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions.
Yi-Wu Shi, Fu-Li Min, Dong Zhou, Bin Qin, Juan Wang, Fa-Yun Hu, Ying-Kit Cheung, Jin-Hua Zhou, Xiang-Shu Hu, Jue-Qian Zhou,[...]. Neurology 2017
53
20

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
213
11

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
922
11

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
K R Crews, A Gaedigk, H M Dunnenberger, J S Leeder, T E Klein, K E Caudle, C E Haidar, D D Shen, J T Callaghan, S Sadhasivam,[...]. Clin Pharmacol Ther 2014
376
11

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
K A Birdwell, B Decker, J M Barbarino, J F Peterson, C M Stein, W Sadee, D Wang, A A Vinks, Y He, J J Swen,[...]. Clin Pharmacol Ther 2015
267
11

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Ursula Amstutz, Linda M Henricks, Steven M Offer, Julia Barbarino, Jan H M Schellens, Jesse J Swen, Teri E Klein, Howard L McLeod, Kelly E Caudle, Robert B Diasio,[...]. Clin Pharmacol Ther 2018
172
11

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Matthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W Fraser Symmans, Howard L McLeod, Mark J Ratain, Hitoshi Zembutsu,[...]. Clin Pharmacol Ther 2018
125
11

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.
Sae-Hoon Kim, Kyung Wha Lee, Woo-Jung Song, Sang-Heon Kim, Young-Koo Jee, Sang-Min Lee, Hye-Ryun Kang, Heung-Woo Park, Sang-Heon Cho, Seong-Ho Park,[...]. Epilepsy Res 2011
165
10

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.
S G Leckband, J R Kelsoe, H M Dunnenberger, A L George, E Tran, R Berger, D J Müller, M Whirl-Carrillo, K E Caudle, M Pirmohamed. Clin Pharmacol Ther 2013
142
10

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
10


Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.
Chaichon Locharernkul, Jakrin Loplumlert, Chusak Limotai, Wiwat Korkij, Tayard Desudchit, Siraprapa Tongkobpetch, Oratai Kangwanshiratada, Nattiya Hirankarn, Kanya Suphapeetiporn, Vorasuk Shotelersuk. Epilepsia 2008
304
10

HLA-B*13:01 and the dapsone hypersensitivity syndrome.
F-R Zhang, H Liu, A Irwanto, X-A Fu, Y Li, G-Q Yu, Y-X Yu, M-F Chen, H-Q Low, J-H Li,[...]. N Engl J Med 2013
148
10

Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.
Chonlaphat Sukasem, Chonlawat Chaichan, Thapanat Nakkrut, Patompong Satapornpong, Kanoot Jaruthamsophon, Thawinee Jantararoungtong, Napatrupron Koomdee, Suthida Sririttha, Sadeep Medhasi, Sarawut Oo-Puthinan,[...]. J Immunol Res 2018
24
41

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.
Maja Mockenhaupt, Cecile Viboud, Ariane Dunant, Luigi Naldi, Sima Halevy, Jan Nico Bouwes Bavinck, Alexis Sidoroff, Jürgen Schneck, Jean-Claude Roujeau, Antoine Flahault. J Invest Dermatol 2008
555
10

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
Kelly E Caudle, Teri E Klein, James M Hoffman, Daniel J Muller, Michelle Whirl-Carrillo, Li Gong, Ellen M McDonagh, Katrin Sangkuhl, Caroline F Thorn, Matthias Schwab,[...]. Curr Drug Metab 2014
209
10

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Shuen-Iu Hung, Wen-Hung Chung, Lieh-Bang Liou, Chen-Chung Chu, Marie Lin, Hsien-Ping Huang, Yen-Ling Lin, Joung-Liang Lan, Li-Cheng Yang, Hong-Shang Hong,[...]. Proc Natl Acad Sci U S A 2005
779
9

Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
Shuen-Iu Hung, Wen-Hung Chung, Zhi-Sheng Liu, Chien-Hsiun Chen, Mo-Song Hsih, Rosaline Chung-yee Hui, Chia-Yu Chu, Yuan-Tsong Chen. Pharmacogenomics 2010
185
9

HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.
Ying-Kit Cheung, Suk-Hang Cheng, Ernest J M Chan, Su V Lo, Margaret H L Ng, Patrick Kwan. Epilepsia 2013
117
9

Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.
Timir Y Mehta, Laxman M Prajapati, Bharti Mittal, Chaitanya G Joshi, Jayesh J Sheth, Dinesh B Patel, Dinkar M Dave, Ramesh K Goyal. Indian J Dermatol Venereol Leprol 2009
199
9

HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.
E Genin, D-P Chen, S-I Hung, P Sekula, M Schumacher, P-Y Chang, S-H Tsai, T-L Wu, T Bellón, R Tamouza,[...]. Pharmacogenomics J 2014
138
9

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
M A Martin, J M Hoffman, R R Freimuth, T E Klein, B J Dong, M Pirmohamed, J K Hicks, M R Wilkinson, D W Haas, D L Kroetz. Clin Pharmacol Ther 2014
74
12

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
John F Greden, Sagar V Parikh, Anthony J Rothschild, Michael E Thase, Boadie W Dunlop, Charles DeBattista, Charles R Conway, Brent P Forester, Francis M Mondimore, Richard C Shelton,[...]. J Psychiatr Res 2019
87
10

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Kelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, Jesse J Swen, Cyrine E Haidar, Teri E Klein, Roseann S Gammal, Mary V Relling, Stuart A Scott, Daniel L Hertz,[...]. Clin Transl Sci 2020
132
9

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
Jason H Karnes, Allan E Rettie, Andrew A Somogyi, Rachel Huddart, Alison E Fohner, Christine M Formea, Ming Ta Michael Lee, Adrian Llerena, Michelle Whirl-Carrillo, Teri E Klein,[...]. Clin Pharmacol Ther 2021
25
36

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Christine Lonjou, Nicolas Borot, Peggy Sekula, Neil Ledger, Laure Thomas, Sima Halevy, Luigi Naldi, Jan-Nico Bouwes-Bavinck, Alexis Sidoroff, Claudia de Toma,[...]. Pharmacogenet Genomics 2008
396
8

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.
E J Stanek, C L Sanders, K A Johansen Taber, M Khalid, A Patel, R R Verbrugge, B C Agatep, R E Aubert, R S Epstein, F W Frueh. Clin Pharmacol Ther 2012
268
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.